期刊
JOURNAL OF CONTROLLED RELEASE
卷 240, 期 -, 页码 24-37出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2015.10.012
关键词
Nanotechnology; Nanoparticle; Protein delivery; Therapy; Non-invasive administration
资金
- National Institutes of Health (NIH) [EB015419, R00CA160350, U54-CA151884]
- Movember-Prostate Cancer Foundation (PCF) Challenge Award
- PCF Young Investigator Award
- David Koch-PCF Program in Nanotherapeutics
- National Research Foundation of Korea [K1A1A2048701]
Protein-based therapeutics havemade a significant impact in the treatment of a variety of important human diseases. However, given their intrinsically vulnerable structure and susceptibility to enzymatic degradation, many therapeutic proteins such as enzymes, growth factors, hormones, and cytokines suffer from poor physicochemical/biological stability and immunogenicity that may limit their potential benefits, and in some cases limit their utility. Furthermore, when protein therapeutics are developed for intracellular targets, their internalization and biological activity may be limited by inefficient membrane permeability and/or endosomal escape. Development of effective protein delivery strategies is therefore essential to further enhance therapeutic outcomes to enable widespread medical applications. This review discusses the advantages and limitations of marketed and developmental-stage protein delivery strategies, and provides a focused overview of recent advances in nanotechnology platforms for the systemic delivery of therapeutic proteins. In addition, we also highlight nanoparticle-mediated non-invasive administration approaches (e.g., oral, nasal, pulmonary, and transdermal routes) for protein delivery. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据